HX 016 9
Alternative Names: HX-016-9Latest Information Update: 31 Jul 2025
At a glance
- Originator HanX Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 May 2025 HX 016 9 is available for licensing as of 31 Jul 2025. http://hanxbio.com/jszx
- 19 May 2025 HanX Biopharmaceuticals announces intention to submit an Investigational New Drug application for Solid tumours by the end of 2026
- 07 May 2025 Preclinical trials in Solid tumours in China (Parenteral) prior to May 2025